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Abstract 
The association of anthropometric (waist circumference) and hemodynamic (blood pressure) changes with abnormal‑
ities in glucose and lipid metabolism has been motivation for a lot of discussions in the last 30 years. Nowadays, blood 
pressure, body mass index/abdominal circumference, glycemia, triglyceridemia, and HDL‑cholesterol concentrations 
are considered in the definition of Metabolic syndrome, referred as Visceral adiposity syndrome (VAS) in the present 
review. However, more than 250 years ago an association between visceral and mediastinal obesity with hyperten‑
sion, gout, and obstructive apnea had already been recognized. Expansion of visceral adipose tissue secondary to 
chronic over‑consumption of calories stimulates the recruitment of macrophages, which assume an inflammatory 
phenotype and produce cytokines that directly interfere with insulin signaling, resulting in insulin resistance. In turn, 
insulin resistance (IR) manifests itself in various tissues, contributing to the overall phenotype of VAS. For example, 
in white adipose tissue, IR results in lipolysis, increased free fatty acids release and worsening of inflammation, since 
fatty acids can bind to Toll‑like receptors. In the liver, IR results in increased hepatic glucose production, contribut‑
ing to hyperglycemia; in the vascular endothelium and kidney, IR results in vasoconstriction, sodium retention and, 
consequently, arterial hypertension. Other players have been recognized in the development of VAS, such as genetic 
predisposition, epigenetic factors associated with exposure to an unfavourable intrauterine environment and the gut 
microbiota. More recently, experimental and clinical studies have shown the autonomic nervous system participates 
in modulating visceral adipose tissue. The sympathetic nervous system is related to adipose tissue function and dif‑
ferentiation through beta1, beta2, beta3, alpha1, and alpha2 adrenergic receptors. The relation is bidirectional: sympa‑
thetic denervation of adipose tissue blocks lipolysis to a variety of lipolytic stimuli and adipose tissue send inputs to 
the brain. An imbalance of sympathetic/parasympathetic and alpha2 adrenergic/beta3 receptor is related to visceral 
adipose tissue storage and insulin sensitivity. Thus, in addition to the well‑known factors classically associated with 
VAS, abnormal autonomic activity also emerges as an important factor regulating white adipose tissue, which high‑
lights complex role of adipose tissue in the VAS.
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Background
As the global epidemic of obesity that emerged in the lat-
ter part of the 20th century A.D. continues into the 21st 
century, a syndrome comprised of risk factors for cardio-
vascular disease has growing health and economic impli-
cations worldwide. This syndrome has various names, of 
which the best known is probably Metabolic Syndrome. 
A key driver of the obesity epidemic and related car-
diometabolic complications is ‘access to excess’ calories, 
sugar, fat, salt, labor saving devices and passive entertain-
ment. And, while the epidemic had its roots in developed 
economies ~40 years ago, during the past 10–20 years it 
has firmly established residence in most emerging econo-
mies. In addition to increasingly prevalent overweight 
and obesity, mean age is also increasing as birth rates 
slow in many nations, which further drives this condi-
tion. To further amplify risk, in the United States and 
Europe, the Euro-Caucasian population is growing pro-
portionately less than other racial-ethnic groups, which 
are typically more susceptible to the ‘diabetogenic’ effects 
of ‘access to excess’. These observations provide evi-
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incompletely defined interplay of genetic, environmental, 
and developmental factors.
Given the constellation and complex interaction of fac-
tors underlying the development of Metabolic Syndrome, 
this is an especially opportune time to review its history 
and summarize an array of important physiopathologic 
insights. It is our intent that this information will stimu-
late progress in preventing and managing this condition 
and further scientific inquiry to lessen its adverse global 
health and economic impact.
Historical aspects
More than 250 years ago, JB Morgagni described an asso-
ciation between visceral and mediastinal obesity, hyper-
tension, gout, and obstructive sleep apnea [1]. He used 
only a knife for anatomical dissection and his skills to 
provide the first observations about a cluster of cardio-
vascular risk factors that we will refer as Visceral Adipos-
ity Syndrome (VAS).
The next three landmarks reports were published in the 
1920s. First, two physicians from Vienna, Karl Hitzen-
berger, and Martin Richter–Quittner made clinical 
observations during World War I that led to two papers 
on metabolic factors, hypertension, diabetes and vascular 
disease [2, 3]. Second, Eskil Kylin, a Swedish physician, 
described an association between hypertension, hyper-
glycemia, obesity, and hyperuricemia [4].
Third, William Preble, a Boston physician, made obser-
vations from 1000 patients and insurance data, which led 
him to conclude that “overweight of 15 or more pounds 
is an increasingly serious condition with advancing years, 
conducive to heart, arterial and kidney disease, diabetes 
and hypertension”. He reported that albuminuria was 
common in overweight patients and documented they 
were more likely to die from diabetes, heart disease, other 
circulatory diseases and kidney disease. He also observed 
that weight loss reduced blood pressure and albuminuria 
[5]. Preble concluded, “…It is the duty of the physician to 
acquaint his patient and the community with the gravity 
of the condition (overweight and obesity)…”.
Insulin resistance, an important mechanism for the 
VAS was considered as a risk factor for diabetes in the 
1930s by Himsworth [6–8]. In the 1940s and 1950s, Jean 
Vague, a French physician, described a strong relation-
ship between android fat distribution and type 2 diabetes, 
atherosclerosis, and gout [9, 10]. In the 1960s, Albrink 
and Meigs described relationships between obesity 
(skinfold thickness), dyslipidemia and dysglycemia [11]. 
Moreover, Avogaro and Crepaldi described the associa-
tion between hyperlipidemia, obesity, hypertension, dia-
betes and coronary artery disease, which they called the 
Plurimetabolic Syndrome [12]. In the late 1970s, German 
investigators [13, 14] described the association between 
obesity, hypertension, hyperlipidemia, and diabetes and 
originated the term Metabolic Ssyndrome.
Additional important observations followed in the 
late 1980s and early 1990s. Reaven described Syndrome 
X and called attention to insulin resistance as a central 
feature linking diabetes and impaired glucose tolerance, 
elevated triglycerides and reduced HDL-cholesterol, and 
hypertension [15]. Kaplan then described the Deadly 
Quartet comprised of upper body obesity, glucose intol-
erance, hypertriglyceridemia and hypertension [16]. 
Ferrannini and colleagues discussed the same cluster of 
cardiovascular risk factors and found the term Insulin 
resistance syndrome more appropriate [17].
In 1985, Ohlson et al. reported that body fat distribu-
tion was an important risk factor for diabetes after a fol-
low-up of 13.5 years [18]. In a prospective cohort study, 
body fat distribution was related to cardiovascular risk in 
women [19]. Several subsequent studies, summarized in 
reviews and meta-analyses, found that VAS was related 
to increased risk for cardiovascular disease [20], chronic 
kidney disease [21], and several types of cancer [22].
In 1998 [23] the World Health Organization was the 
first organization to provide a unified definition of Met-
abolic Syndrome (Table  1) with diabetes or impaired 
glucose tolerance (IGT) as major clinical features. In 
patients without diabetes or IGT, glucose uptake in the 
lowest quartile during a euglycemic hyperinsulinemic 
clamp also sufficed as evidence for insulin resistance. 
Individuals required, at least, two other clinical features 
including hypertension, hypertriglyceridemia, low-HDL, 
obesity or elevated waist: hip ratio or microalbuminuria.
In 1999, The European Group for the Study of Insulin 
Resistance [24] proposed that three of five clinical cri-
teria were sufficient to define the Metabolic Syndrome, 
including insulin resistance and two or more of cen-
tral obesity, high triglycerides or low HDL, hyperten-
sion, and fasting glucose ≥6.1 mmol/L (Table 1). In 2001 
[25], the National Cholesterol Education/Adult Treat-
ment Panel III proposed that Metabolic syndrome was 
defined by three or more of waist circumference  >40 
inches (102 cm) in men or >35 inches (88 cm) in women, 
fasting glucose  ≥110  mg/dL (6.1  mmol/L), subse-
quently revised to  ≥100  mg/dL (5.6  mmol/L) or treat-
ment for diabetes, blood pressure ≥130  mmHg systolic 
or  ≥85  mmHg diastolic or treatment for hypertension, 
triglycerides  ≥150  mg/dL (1.7  mmol/L), or HDL  <50 
(1.3 mmol/L) for women or <40 mg/dL (1.0 mmol/L) for 
men. The International Diabetes Federation [26] adopted 
waist circumference, defined with ethinicity specific 
values, as a sine qua non criteria for the Metabolic Syn-
drome diagnosis.
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The subsequent sections summarize concepts and 
research which have highlighted various important facets 
of the VAS following these seminal reports.
Insulin resistance and tissue inflammation
Insulin resistance is defined as the reduction of the meta-
bolic (but not mitogenic) effects of insulin following its 
binding to the insulin receptor. Insulin resistance involves 
impaired activation of insulin substrate 1 (IRS1) and, 
subsequently, of the phosphatidylinositol 3-kinase (PI3K) 
pathway in insulin-sensitive tissues [27]. Visceral adi-
posity is strongly associated with insulin resistance, but 
genetic and other factors also predispose to the devel-
opment of this condition, since there are obese patients 
without insulin resistance as well as lean individuals who 
are resistant [28]. An interesting point to consider is that 
individuals who have subnormal amounts of adipose tis-
sue, such as the ones presenting monogenic lipodystro-
phy, also develop severe IR. This fact corroborates the 
hypothesis that adipose tissue failure (loss of capacity of 
expanding to store excess calories) is more important in 
the pathogenesis of VAS than the degree of obesity [29].
Several complex and interwoven mechanisms under-
lie IR in the presence of visceral adiposity, and some of 
them will be shortly addressed. The first question to be 
answered is why visceral fat? It is well established that 
visceral and subcutaneous white adipose tissues (WAT) 
are different concerning adipocyte size and metabolic 
activity [30]. This includes the ability to respond to the 
antilipolytic effects of insulin and to the lipolytic effects 
of catecholamines, which are, respectively, lower and 
higher in visceral than in subcutaneous tissue [31], fea-
turing visceral WAT as more pathogenic [30].
Chronic over-consumption of nutrients concomitantly 
with insufficient energy expenditure exceed the storage 
capacity of glycogen and triglycerides by the “profes-
sional” metabolic tissues, namely, liver, muscle and WAT. 
In such situation, other tissues are exposed to supraphys-
iological concentrations of these nutrients, where they 
exert deleterious effects [32].
Saturated fatty acids, for instance, can bind to recep-
tors that participate in pathogen recognition and innate 
immunity, the Toll-like receptors (TLR) 2 and 4, espe-
cially in adipocytes and macrophages. The consequent 
induction of c-Jun N-terminal kinase (JNK) results 
in phosphorylation of IRS1 in the amino acids ser-
ine (instead of tyrosine, which is phosphorylated under 
physiological conditions), decreasing insulin receptor 
signaling. The activation of the aforementioned pro-
inflammatory pathway also stimulates the transcription 
factor nuclear factor kappa B (NFkB), resulting in the 
production of inflammatory cytokines such as tumor 
necrosis factor alpha (TNFα) and interleukin (IL) 6 [33]. 
These cytokines amplify the JNK signaling pathway and 
further contribute to impaired signaling through the 
insulin receptor [34].
Simultaneously, the expansion of WAT secondary to 
increased caloric intake leads to necrosis/apoptosis of 
hypertrophic adipocytes and release of large fat drop-
lets. The fat droplets are toxic to the surrounding cells 
and eventually stimulate the recruitment of bone marrow 
macrophages, leading to a significant increase of these 
cells in the WAT of obese subjects. These macrophages, 
probably stimulated by cellular debris, assume an inflam-
matory phenotype, also known as classic or M1, charac-
terized by the expression of proinflammatory cytokines 
(TNFα, IL1 and IL6), which aggravate insulin resistance. 
M1 macrophages differ from the macrophages that reside 
in the WAT of lean individuals, which present a pheno-
type known as M2 or alternative, characterized by the 
Table 1 Metabolic syndrome definitions provided by various authorities
WHO World Health Organization, EGIR European Group for the study of Insulin resistance, ATP adult treatment panel, IDF international diabetes federation, IGT 
impaired glucose tolerance, IFG impaired fasting glucose, T2D type 2 diabetes, BMI body mass index, WHR waist:hip ratio, Htn hypertension, Rx pharmacologic 
treatment, alb albumin, ACR albumin:creatinine ratio
Authority, yr WHO 1998 EGIR 1999 ATP III (2001/4) IDF 2005
Insulin resistance IGT, IFG, T2D; insulin  
resistance + 2 below
Plasma insulin >75th  
percentile + 2 below
None; any 3 of the 5 below None
BMI or body fat  
distribution
Men WHR >0.90
Women WHR >0.85 or 
BMI >30
WC ≥94 cm men or ≥80 cm 
women
WC >102 cm men or >88 cm 
women
Increased WC (pop. 
specific) + 2 below
Lipids TG ≥150 mg/dL
HDL <35 men or <39 women
TG ≥ 150 mg/dL
HDL <39 in men or women
TG ≥150 mg/dL
HDL <40 men or <50 women
TG ≥150 mg/dL or Rx, 
HDL <40 men or <50 
women or Rx
Glucose IGT, IFG, T2D IGT or IFG ≥110 mg/dL ≥100 mg/dL or diabetes
Blood pressure ≥140/≥90 ≥140/≥90 or Htn Rx ≥130/≥85 ≥130/≥85 or Htn Rx
Other Urine alb >20 mg /min; 
ACR >30 mg/g
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expression of anti-inflammatory cytokines such as IL10 
and transforming growth factor-beta (TGFβ) [32].
The activation of the JNK pathway by TNFα and IL6 
together with the oxidative stress triggered by the excess 
of nutrients downregulate the expression of adiponectin 
(and their receptors), a hormone produced by adipocytes. 
Adiponectin exerts anti-inflammatory effects, increases 
transport and uptake of fatty acids by muscles, stimu-
lates glucose uptake by muscle and WAT and decreases 
hepatic glucose production. Therefore, low adiponectin 
concentrations contribute to impaired glucose homeo-
stasis and insulin resistance [35].
Insulin resistance manifests itself differentially in vari-
ous tissues, which contributes to the overall phenotype of 
VAS. For example, insulin resistance in: (1) WAT, results 
in lipolysis, increasing free fatty acids into the circula-
tion, which exacerbate the deleterious cycle of hyperlipi-
demia—inflammation—insulin resistance; (2) the liver, 
results in increased hepatic glucose production (via gly-
cogenolysis and gluconeogenesis), contributing to hyper-
glycemia [32]. Hepatic insulin resistance also stimulates 
the synthesis of hepatocyte growth factor (HGF) [36] and 
betatrophin [37], growth factors produced by the liver 
(and also by the fat tissue) that stimulate β-cell hyperpla-
sia, which with other factors, such as free fat acids and 
glucose, contributes to the compensatory hyperinsuline-
mia that often accompanies and actually worsens IR [38]; 
(3) skeletal muscle, a tissue with marked metabolic flex-
ibility to consume and store glucose and lipids, results 
in increased content of free fatty acids and triglycerides 
[39], maintaining the vicious cycle hyperlipidemia—
inflammation—insulin resistance; (4) in the central nerv-
ous system (CNS), at least in animal models, results in 
hyperphagia and increased fat mass [40];(5) in pancre-
atic β-cells results in diminished inhibition of glucagon 
secretion by insulin; the consequent hyperglucagonemia 
increases hepatic glucose production, contributing to 
hyperglycemia [41]; (6) in pancreatic β-cells results in 
reduced glucose-stimulated insulin secretion [42] and, in 
rodents, in lower pancreatic content of insulin [43]; (7) in 
the vascular endothelium results in vasoconstriction and, 
consequently, arterial hypertension, since insulin nor-
mally induces PI3K-dependent production of nitric oxide 
and vasodilatation [44]; (8) in the kidney results in anti-
natriuresis at several sites along the renal tubule, causing 
sodium retention [45] as well as in increased circulating 
concentrations of components of the renin-angiotension-
aldosterone system [46], both changes contributing to 
hypertension.
Insulin resistance in some of the former target sites 
aggravates glycemic homeostasis, increasing the forma-
tion of advanced glycation end products (AGEs). AGEs 
are derived from non-enzymatic reactions between 
glucose and proteins, nucleic acid and lipids. Endog-
enously derived AGEs, as well as exogenously generated 
AGEs formed during high-heat cooking, can promote 
inflammation. This happens via receptors that bind 
to advanced glycation end products, such as RAGE 
(advanced glycosylation end product-specific receptor), 
TLR4 and other receptors that regulate the activity of 
NFκB [47], constituting another link between diet and 
insulin resistance.
An interesting aspect that deserves attention concerns 
the effects of compensatory hyperinsulinemia: although 
it is usually considered a by-product of the insulin resist-
ance, hyperinsulinemia exerts its effects, overstimulating 
certain pathways of insulin action in various cells [27]. 
For instance, the expression of Sterol Regulatory Ele-
ment Binding Protein 1c (SREBP1c), a transcription fac-
tor that modulates the expression of lipogenic enzymes, 
is increased by chronic hyperinsulinemia in the liver of 
mice exhibiting insulin resistance. As a result, de novo 
fatty acid biosynthesis is enhanced and contributes 
to non-alcoholic fatty liver disease (NAFLD) [48], the 
hepatic component of the VAS. Another potential con-
sequence of prolonged hyperinsulinemia is the exacerba-
tion of inflammation since it has been demonstrated that 
in vitro, insulin exerts long-term proinflammatory action, 
by amplifying effects of the cytokine-NFkB axis [49]. An 
important implication of hyperinsulinemia that needs 
to be clearly established is whether neoplastic cells in 
patients with insulin resistance remain sensitive to insu-
lin’s proliferative actions. If so, then hyperinsulinemia 
could be one of the mechanisms proposed to explain the 
increased frequency of cancer that accompanies the obe-
sity epidemic [50]. Other mechanisms that may explain 
the increased cancer risk include the mitogenic effect of 
insulin through either insulin-like growth factor-1 (IGF1) 
receptors or through hybrid IGF1-insulin receptors as 
well as the increased concentrations of free IGF1, as a 
consequence of the lower concentrations of IGF binding 




During embryonic development, there is significant 
plasticity, which attempts to adjust the foetal gene 
expression to the environment, so that the resulting phe-
notype is adapted to the environmental conditions [52]. 
Thus, fetuses exposed to suboptimal conditions during 
intrauterine life (for instance, protein-calorie undernu-
trition) undergo alterations in gene expression to adjust. 
However, if the post-natal life provides different condi-
tions from those previously anticipated (for instance, 
abundance of nutrients), the body will not be prepared 
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for that environment, and is more likely to develop dis-
ease [53].
This ability to sustain the changes acquired in intrau-
terine life in the post-natal life relies on epigenetic mech-
anisms, namely, post-translational modifications within 
histones, DNA cytosine methylation and control of gene 
expression by micro-non-coding RNAs. These molecu-
lar processes occur around the DNA, are stable during 
mitosis and can regulate genome activity regardless of 
DNA sequence [54]; they allow cells to respond quickly 
to environmental modifications and “remember” these 
responses even after removal of the causative stimulus 
[55].
The Dutch famine has been used to investigate the 
effects of in utero stress among adults who were born 
in the western part of The Netherlands at the end of 
World War II. These individuals were exposed prenatally 
to undernutrition. The Dutch Famine Cohort study has 
shown that individuals exposed to maternal undernutri-
tion at any stage of gestation had increased glycaemia as 
adults. Women exposed to undernutrition at early stages 
of gestation appeared to be more centrally obese than 
those not prenatally exposed to famine [56]. Interest-
ingly, higher methylation of genes related to metabolic 
and cardiovascular diseases, such as the ones encoding 
leptin, IL10 and ABCA1 were found in individuals prena-
tally exposed to famine in comparison to their unexposed 
same-sex siblings [57]. In the same line of investigation, 
specific associations of low birth weight with VAS were 
observed in other populations [58, 59], strongly suggest-
ing that, besides environmental and genetic conditions, 
prenatal reprogramming participates in the susceptibility 
to the VAS.
Microbiota
Another player recently recognized as important in the 
development of VAS is the gut microbiota, comprised 
of approximately 100 trillion microbes resident in the 
human intestines, the majority of them belonging to the 
phyla Firmicutes and Bacteroidetes. The gut microbiota is 
influenced by diet composition, which, in turn, influences 
how food is processed in the gastrointestinal tract [60].
Pathobionts (resident microbes with pathogenic poten-
tial) [61] increase by diets enriched in saturated fat, 
damage the intestinal epithelial cell layer and enable the 
translocation of one key constituent of many bacteria, 
lipopolysaccharide (LPS), from the gut lumen into the 
systemic circulation [62]. LPS molecules bind to TLRs, 
activating the proinflammatory signaling cascades pre-
viously mentioned and eliciting insulin resistance; in 
the liver, for instance, activation of TLR4 and TLR9 aug-
ments TNFα secretion and participates in NAFLD devel-
opment [60].
On the other hand, a fiber-rich diet exerts beneficial 
effects on the microbiota composition, decreasing the 
Firmicutes: Bacteriodetes ratio and consequently increas-
ing fiber degradation and the production of short-chain 
fatty acids, such as acetate, propionate, and butyrate [63], 
which are absorbed in the colon. Acetate and propionate 
are substrates for lipogenesis and gluconeogenesis while 
butyrate provides energy for colonic epithelial cells [60]. 
Additionally, these compounds bind to widely expressed 
G-protein coupled receptors (GPR41 and GPR43), aug-
menting energy expenditure, insulin sensitivity, satiety 
and production of glucagon-like peptide 1 (GLP1) and 
decreasing inflammation, thereby protecting against VAS 
[62].
Autonomic modulation of visceral adipose tissue
The CNS is an important modulator of food intake 
through different hormonal and neuropeptide signal-
ing pathways [64]. Neuropeptides regulate energy stor-
age in white adipocytes and inhibit brown adipose tissue 
activation in mammals [65]. Experimental and clinical 
studies showed a relation between the autonomic nerv-
ous system, dietary intake and adipose tissue. Body fat 
distribution of body fat is a more important risk factor 
for the development of hypertension and cardiovascu-
lar disease than obesity generally. Sympathetic nervous 
system (SNS) activity contributes to obesity-induced 
hypertension [66]. Independently of body fat distribu-
tion, sympathetic activity seems to be related to differ-
ent components of the VAS. By stratifying patients with 
similar obesity degrees according to the presence or 
absence of high blood pressure, we found a higher sur-
rogate markers of sympathetic activity derived from 
spectral analysis and greater impairment in several 
components of Metabolic syndrome in those subjects 
with high blood pressure [67]. It suggest that high blood 
pressure carriage in pararel with sympathetic activity in 
this population. Nonetheless, SNS activity was associ-
ated to obesity in obese normotensive subjects [68]. The 
distribution of body fat seems to be more important to 
determine the cardiovascular risk than the whole body 
fat. Alvarez et al. showed a higher sympathetic activity in 
men with visceral obesity compared to subcutaneous fat 
levels [69]. Leptin, an important product of visceral adi-
pocytes, is related to increased sympathetic activity, with 
human obesity-induced hypertension, and associated to 
a increased termogenic metabolism [70]. The SNS also 
plays a role in the regulation of mammalian thermogen-
esis and contributes to changes in energy expenditure 
that accompany changes in diet. The energy imbalance 
resulting from metabolic heat in response to cold expo-
sure and to diet intake is covered by the sympathetic 
nervous system, which suggest an unequivocal relation 
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between sympathetic activity and body fat deposition 
[71]. Even in healthy subjects body fat showed a direct 
relationship with SNS activity [72]. Grassi et  al. evalu-
ating normal control subjects, subjects with peripheral 
and central obesity showed a greater sympathetic activ-
ity in subjects with central obesity [73]. A recent study 
analyzed the effects of surgically-induced weight loss 
in severely obese patients and showed an important 
reduction in insulin resistance index, leptin levels, and 
sympathetic activity [74]. Abdominal adiposity loss is 
associated with diabetogenic and atherogenic mark-
ers. In a study evaluating peripheral and central obesity 
a moderate weight loss (5–10  %) was associated with 
approximately a 30  % decline of visceral adipose tissue 
[75]. Different studies suggest a straight relationship 
between sympathetic activity and central WAT [66, 73]. 
The relation is bidirectional; sympathetic denervation 
of WAT blocks lipolysis to a variety of lipolytic stimuli 
and the use of anterograde transneural viral tracers has 
defined the sensory input from WAT to the brain [76]. 
These experiments show the importance of sympathetic 
innervation in WAT.
The effects of parasympathetic innervation of the adi-
pose tissue are partially elucidated. Kreier et  al. used a 
retrograde transneuronal tracer, i.e., pseudorabies virus, 
in intra-abdominal fat pads of sympathetically dener-
vated rats to evaluate parasympathetic innervation in 
adipose tissue [77]. They demonstrated that parasympa-
thetic denervation of WAT significantly reduced insulin-
dependent glucose and free fat acid uptake and increased 
the sensitivity of lipase hormone-sensitive, resulting in an 
increased intracellular triglyceride breakdown. Thus, evi-
dence suggests that the parasympathetic system is associ-
ated with adipogenesis (triglycerides synthesis), whereas 
the sympathetic system is associated with lipolysis (tri-
glycerides breakdown) in WAT.
SNS modulation of visceral adipose tissue is related 
to different adrenergic receptors. Adipocyte plasma 
membranes express beta-1 (β1), beta-2 (β2), beta-3 (β3), 
alpha-1(α1), and alpha-2 (α2) adrenergic receptors [78]. 
The balance between alpha and beta adrenergic receptors 
emerges as an important variable in regulating adipo-
cyte cell number. Using a murine model with genetically 
altered balance alpha2/beta3 adrenoreceptors, Valet et al. 
demonstrated adipocyte hyperplasia [79]. The fasting 
state is associated with adipolysis, which is modulated 
mainly by the β3 adrenergic receptor. Conversely, adipo-
genesis is associated with activation of the parasympa-
thetic system, but the receptor mediating adipogenesis 
is not well defined [76]. A sympathetic/parasympathetic 
imbalance as well as an α2 adrenergic/β3 receptor imbal-
ance are related to visceral adipose tissue storage and 
insulin sensitivity.
Thus, in addition to the well-known factors classically 
associated with VAS, the literature suggests an impor-
tant role for autonomic activity in the regulation of WAT, 
which highlights the complex role of adipose tissue in the 
VAS.
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